Clinical observation on adefovir dipivoxil in the treatment of 64 patients with lamivudine-resistant chronic hepatitis B

Objective To observe the therapeutic effect of the single-use adefovir dipivoxil and adefovir dipivoxil combined with lamivudine (LAM) on patients with lamivudine-resistant chronic hepatitis B.Methods 64 patients with lamivudine-resistant chronic hepatitis B admitted from January 2006 to January 2008 in our hospital including out-patients and in-patients were randomly divided into observation group and control group.The patients in observation group,on the basis of routine treatment,were treated by adefovir dipivoxil combined with lamivudine,however,the patients in control group were treated by adefovir dipivoxil only for 72 weeks in both groups.The serum HBV DNA levels,HBV serum markers,liver functional changes and adverse reactions were observed.Results At 48 weeks after treatment,the HBV DNA negative conversion rate in observation group was 68.8% (22/32),which was 34.4% (11/32) in control group,and there was a significant difference between the two groups (P0.01).The HBeAg/anti-HBe conversion rate in observation group was 28.1% (8/32),which was 6.25% (2/32) in control group,and there was a significant difference between the two groups (P0.05).The ALT normalization rate in observation group was 71.9% (23/32),which was 34.4% (11/32) in control group,and there was a significant difference between the two groups (P0.01).Conclusion The adefovir dipivoxil combined with lamivudine is superior to lamivudine only in the treatment of lamivudine-resistant chronic hepatitis B,which is worthy of application in clinic.